AbstractsEfficacy and safety of third-line treatment with anlotinib in patients with refractory advanced non-small-cell lung cancer (ALTER-0303): a randomised, double-blind, placebo-controlled phase 3 study
References (0)
Cited by (0)
Copyright © 2017 Elsevier Ltd. All rights reserved.